Showing results (941-950 of 1,516) with videos related to
Sort By:
Pageof 152
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcomaBart C Kuenen, Jose Tabernero, Jose Baselga, et al.Blood|May 23, 1998
Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomesJ A Pérez-Simón, R García-Sanz, M D Tabernero, et al.International Journal of Radiation Oncology, Biology, Physics|June 3, 2015
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C TrialFrancesco Sclafani, Clare Peckitt, David Cunningham, et al.International Journal of Radiation Oncology, Biology, Physics|June 6, 2017
Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter StudyJuan Morote, Ángel José Tabernero, José Luis Álvarez Ossorio, et al.Journal of Molecular Biology|February 10, 1995
Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombinL Tabernero, C Y Chang, S L Ohringer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2013
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimensKimmie Ng, Josep Tabernero, Jimmy Hwang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumorsB Markman, J Tabernero, I Krop, et al.Cancers|May 28, 2022
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer CellsChiara Bellio, Marta Emperador, Pol Castellano, et al.Virus Research|January 2, 2017
Deep sequencing in the management of hepatitis virus infectionsJosep Quer, Francisco Rodríguez-Frias, Josep Gregori, et al.Cancer Chemotherapy and Pharmacology|March 13, 2008
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphismsAlbert Font, Ramon Salazar, Joan Maurel, et al.Pageof 152